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Purpose The main goal of this study was to encapsulate Pioglitazone (PGZ), in 
biodegradable polymeric nanoparticles as a new strategy for the treatment of ocular 
inflammatory processes. 
Methods To improve their biopharmaceutical profile for the treatment of ocular 
inflammatory disorders, nanospheres (NSs) of PGZ were formulated by factorial design 
with poly (lactic-co-glycolic acid) polyethylene glycol (PLGA-PEG). Interactions drug-
polymer have been carried out by spectroscopic (X-ray spectroscopy, FTIR) and thermal 
methods (DSC). The PGZ-NSs were tested for their in vitro release profile, cytotoxicity, 
and ocular tolerance (HET-CAM test); ex vivo corneal permeation, and in vivo 
inflammatory prevention and bioavailability. 
Results The optimized system showed a negative surface charge of -13.9 mV, an average 
particle size (Zav) of around 160 nm, a polydispersity index (PI) below 0.1, and a high 
encapsulation efficiency (EE) of around 92%. According to the DSC results, the drug was 
incorporated into the NSs polymeric matrix. The drug release was sustained for up to 14 
hours. PGZ-NSs up to 10 µg/ml exhibited no retinoblastoma cell toxicity. The ex vivo 
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corneal and scleral permeation profiles of PGZ-NSs showed that retention and permeation 
through the sclera were higher than through the cornea. Ocular tolerance in vitro and in 
vivo demonstrated the non-irritant character of the formulation. 
Conclusion The in vivo anti-inflammatory efficacy of developed PGZ-NSs indicates this 
colloidal system could constitute a new approach to prevent ocular inflammation.  
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thiazolidine-2,4-diona) belongs to the class of the thiazolidinediones (TZDs) for clinical 
treatment of type 2 diabetes. This drug is an agonist of the peroxisome proliferator-
activated receptor (PPARγ) it is significantly important in the regulation of the immune 
and inflammatory responses. The anti-inflammatory effects are induced as a response to 
a negative regulation of macrophage activation and differentiation. Previous studies into 
PPARγ receptors have reported functions such as: anti-inflammatory, anti-angiogenic, 
antifibrotic, anti-tumor effects, and neuroprotection. Moreover , it has a protective effect 
on inflammatory ocular process (1-4). 
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PGZ has the capacity to inhibit the local development of several inflammatory factors: 
these included IFN-γ and IL-6 in vivo. This effect was made clear in the measurement of 
intraocular cytokines and chemokines (3). The activation of PPARγ may suppress the 
production of inflammatory factors. This may work through the direct inhibition of their 
production by intraocular monocytes or T cells. PGZ may also operate by inhibiting 
corneal fibroblast migration, thus cutting down on corneal fibroblast-induced collagen 
contraction as the cornea heals (1). In ocular therapies, one of the difficulties is for an 
adequate drug concentration to be delivered to the site of action and sustained. Normally, 
in the cases when ophthalmic formulations are used, less than 5% of the applied drug 
actually permeates the cornea and arrives to the intraocular tissues (5). This problematic 
performance means that it is necessary to instill the formulation several times a day in 
order to achieve the therapeutic efficacy, which is often associated with adverse effects. 
When the drug is retained in the pre-corneal area and the penetration is through to the 
cornea, this is of great benefit to the ophthalmic therapy (5).  
In past studies it is has been indicated that controlled release systems have an interesting 
potential for ocular drug delivery (6-10). These systems may intensify the ocular retention 
through prolonging it. Therefore, different ocular distributions in colloidal carriers greatly 
aid in achieving satisfactory treatment of eye pathologies, with the possibility of targeting 
different eye regions (11). Liposomes and polymeric nanoparticles (NPs) including 
nanospheres (NSs) and nanocapsules, are among the most successful approaches for 
ocular delivery systems. Numerous studies have reported on the effectiveness of 
encapsulation drugs with biodegradable polymers to treat ocular disorders. This is 
because of their biocompatibility and biodegradability, and they show an appropriate drug 
delivery in different tissues of the eye (6,10,12-13). 
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Much attention has been focused on polymeric NPs as potential therapeutic delivery 
systems. Biodegradable polymers, including polylactic-co-glycolic acid (PLGA), 
(approved by European Medicine Agency (EMA) and Food and Drug Administration 
(FDA)) used in various drug delivery systems in humans, exhibit good biocompatibility, 
small and non-toxic particles can be produced (12). All the foregoing renders them 
optimal carriers for entrapping biologically active macromolecular drugs, such as 
polypeptides, proteins, nucleic acids, and vaccine vectors (5). Therefore, they could be a 
valid alternative for the delivery of drugs into the eye. The addition of a second ingredient 
such as Polyethylene glycol (PEG) may make them more versatile in terms of the 
encapsulation and delivery of proteins, and more susceptible to interact with the 
biological surface (14). Thus, studies have shown that PEG coated NPs have crucial 
therapeutic potential ensuring a more controlled release of drugs. The PEG associated 
with the surface of PLGA-NPs creates a hydrophilic coating at the hydrophobic NPs 
surface, with the advantage that these systems are working their (beneficial) effect over a 
greater time period, thus avoiding being recognized by the reticuloendothelial system 
(RES). PEG coating polyester also facilitates the transport of the NPs across the corneal 
epithelium (15). 
The aim of this study was to develop a new ocular delivery system of PGZ loaded PLGA-
PEG NSs determining which factors influence the physicochemical properties of the 
particles and drug entrapment efficiency (EE). The NSs were optimized by a factorial 
design. 
The in vitro release profile, ex vivo transcorneal and transcleral permeations and in vivo 
assays were performed to demonstrate that pioglitazone nanospheres (PGZ-NSs) are 
suitable for the prevention of ocular inflammatory process. Assays of cellular toxicity, 
HET-CAM and Draize test were carried out to confirm that these systems do not induced 
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eye irritation and they could present novel targets so as to act more effectively against 





The PGZ was purchased from Capot Chemical (Hangzhou, P.R. China) and Diblock 
copolymer PLGA-PEG 5% (50:50) Resomer® was obtained from Evonik Corporation 
(Birmingham, USA). Tween (Tw) 80 and acetone were purchased from Sigma-Aldrich 
(Madrid, Spain) and Fisher Scientific (Pittsburgh, USA), respectively. The dialysis 
membrane MWCO 12,000–14,000 Da. was obtained from Medicell International Ltd. 
(London, UK). Fertilized hens’ eggs were obtained from the GALLSA farm (Tarragona, 
Spain). Reagents for cell culture were obtained from Gibco (Alfagene, Portugal). The Y-
79 was acquired from Cell Lines Service (CLS, Eppelheim, Germany) and Alamar Blue 
from Invitrogen Alfagene® (Portugal) was used in order to estimate the cell viability. 
Water filtered through a Millipore MilliQ system was used throughout all the 




Optimization and characterization of PGZ-NSs 
 
PGZ-NSs were obtained by the solvent displacement technique described in accordance 
with Fessi (16). This technique consists of dissolving the polymer and the compound in 
an organic solvent, it being a successful method to deliver the lipophilic drug (13). 
PGZ was previously solubilized in dimethyl sulfoxide (DMSO) (17), then the PLGA-
PEG was dissolved in 5 ml of acetone. Once completely dissolved, they were then mixed 
together. This organic phase was added drop by drop, gently mixing into 10 ml of an 
aqueous solution of Tw 80 (2 %), used as a surfactant to achieve pH 4.5. DMSO, and 
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acetone were evaporated. The NSs dispersion was concentrated to 10 ml under reduced 
pressure (Bücchi B-480, Flawil, Switzerland).  
 
The factorial design was set up so as to optimize in that the PGZ-NSs needed as few 
experiments to be carried out as possible. A five-levels central rotatable composite design 
23 + star was selected to study the main effects and interactions of three independent 
variables (PGZ, PLGA-PEG and Tw 80 concentrations), on four dependent variables 
(average particle size (Zav), polydispersity index (PI), zeta potential (ZP) and EE). A pH 
of 4.5 was kept constant for all the assays. A total of 16 experiments (8 factorial points, 
6 axial points and 2 replicated center points) to estimate the pure error sum of squares 
were required using Statgraphics Plus 5.1 software (Table I). The individual influences 
and the interactions of the three independent variables led to the results and responses 
observed in the experiments, and following on from this the full second-order polynomial 
equation below was used to model them (Eq. 1): 
 
𝑌 = 𝛽0 + 𝛽1𝑋1 + 𝛽2𝑋2 + 𝛽3𝑋3 + 𝛽11𝑋1
2 + 𝛽22𝑋2
2+𝛽33𝑋3
2 + 𝛽12𝑋1𝑋2 + 𝛽13𝑋1𝑋3 + 𝛽23𝑋2𝑋3              
(1) 
 
where 𝑌 is the measured response, 𝛽0 to 𝛽23 are the regression coefficients and X1, X2 
and X3 are the three independent variables. To identify the significance of the effects and 
interactions between them, analysis of variance (ANOVA) was performed for each 
parameter. 
Morphology of PGZ-NSs dispersions was analyzed by transmission electronic 
microscopy (TEM). Prior to negative staining, UV light was used to activate copper grids 
and samples were placed on the grid surface. Samples were diluted (1:3) placed in the 
grids and negative stain was employed with a 2% (v/v) uranyl acetate solution. They were 
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then dried at room temperature and the samples were examined by TEM on a Jeol 1010 
(Tec-nai Spirit TEM, FEI) at 80 kV. 
Morphometry (Zav and PI) of NSs was determined by photon correlation spectroscopy 
(PCS) (after 1:10 dilution) with a Zetasizer Nano ZS (Malvern Instruments, Malvern, 
UK) at 25 ºC, in a disposable quartz cells (Malvern Instruments).  
Surface charge of developed NSs, measured as ZP, was determined by laser-Doppler 
electrophoresis with the M3 PALS system in Zetasizer Nano ZS. ZP measurements can 
give information about the possibility of particles aggregation. A greater ZP (in absolute 
value) results in there being less aggregation coming from repulsion forces between the 
particles. To calculate this, the Henry equation was used [18], according to (Eq. 2):  
     
                      𝜇𝐸 =
𝜀𝑍𝑃𝑓(𝐾𝑎)
6𝜋𝜂
                               (2) 
 
where µE is the electrophoretic mobility, ε is the dielectric constant of the medium, ZP is 
the Zeta potential, η is the viscosity of the medium, K is the Deybye-Hückel parameter 
and f (Ka) is a correction factor fully adjusted for the thickness of the electrical double 
layer (1/K) and the particle diameter (a). The reported values are the average ± SD of at 
least three different formulation batches (19). 
 
To indirectly determine the EE of PGZ-NSs the concentration of the free drug in the 
dispersion medium has been determined previous filtration/centrifugation technique 
(1:10 dilution) by using Ultracell–100K (Amicon® Ultra; Millipore Corporation, 
Billerica, Massachusetts) centrifugal filter devices at 12,000 rpm for 15 minutes. The EE 









𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑃𝐺𝑍 − 𝐹𝑟𝑒𝑒 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑃𝐺𝑍
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High performance liquid chromatography (HPLC) was used in the evaluation of the 
samples. The mobile phase was : acetonitrile, ammonia acetate 0.1M and glacial acetic 
acid, with a flux of 0.7 ml/min and a volume of injection of 10 µl. The reported values 





Table I. Coded and values of the three experimental factors according to the matrix designed by 2
3
 + star central composite 
 rotable factorial design and measured responses. 
 
 
                                     CPGZ                    CPLGA-PEG CTW 80 Measured response 
Factorial 
points Coded level   (mg/ml)   Coded level      (mg)   Coded level   (%)   Zav (nm) PI ZP (mV)  EE (%) 
F1 -1 0.8 -1 90 -1 1.5 152.1 ± 2.4 0.11 ± 0.01 -13.9 ± 0.4 93.97 ± 0.22 
F2 1 1.2 -1 90 -1 1.5 152.9 ± 1.1 0.09 ± 0.01 -10.5 ± 0.1 85.82 ± 1.56 
F3 -1 0.8 1 100 -1 1.5 165.1 ± 2.6 0.16 ± 0.17 -13.0 ± 0.3 91.66 ± 2.13 
F4 1 1.2 1 100 -1 1.5 158.4 ± 0.8 0.12 ± 0.03 -10.9 ± 0.1 84.87 ± 2.31 
F5 -1 0.8 -1 90 1 2.5 151.0 ± 1.1 0.11 ± 0.01 -12.8 ± 0.3 91.15 ± 1.54 
F6 1 1.2 -1 90 1 2.5 152.4 ± 0.8 0.10 ± 0.01 -10.7 ± 0.1 82.01 ± 0.21 
F7 -1 0.8 1 100 1 2.5 165.4 ± 1.7 0.12 ± 0.02 -13.3 ± 0.3 94.47 ± 0.17 
F8 1 1.2 1 100 1 2.5 148.9 ± 2.3 0.10 ± 0.03 -10.9 ± 0.4 81.19 ± 2.32 
F9 1.68 1.34 0 95 0 2.0 161.5 ± 0.6 0.13 ± 0.01 -10.1 ± 0.4 80.45 ± 0.17 
F10 -1.68 0.66 0 95 0 2.0 148.9 ± 0.8 0.12 ± 0.02 -15.6 ± 0.5 92.89 ± 1.23 
F11 0 1 1.68 103.4 0 2.0 152.5 ± 0.1 0.12 ± 0.00 -12.4 ± 0.2 88.24 ± 2.42 
F12 0 1 -1.68 86.6 0 2.0 162.1 ± 0.4 0.12 ± 0.03 -12.5 ± 0.4 93.95 ± 1.32 
F13 0 1 0 95 1.68 2.84 165.0 ± 0.3 0.17 ± 0.01 -12.8 ± 0.2 87.94 ± 1.12 
F14 0 1 0 95 -1.68 1.16 155.0 ± 1.8 0.10 ± 0.01 -13.0 ± 0.5 90.84 ± 1.35 
F15ª 0 1 0 95 0 2.0 158.6 ± 1.7 0.08 ± 0.00 -13.6 ± 0.5 90.17 ± 0.31 
F16ª 0 1 0 95 0 2.0 160.7 ± 2.1 0.10 ± 0.02 -13.9 ± 0.7 91.61 ± 1.72 






To assess the physical state of the PGZ and the possible interactions between the drug 
and the polymer, X-ray spectroscopy came into play, backed by FTIR spectral 
measurements and differential scanning calorimetry (DSC) analysis.  
X-ray spectroscopy was used to analyse the state (amorphous or crystalline) of the PGZ-
NSs. Powder of PGZ, PLGA-PEG, and NSs was sandwiched between films of polyester 
and exposed to CuK” radiation (45 kV, 40 mA, λ = 1.5418 Å) in the range 2ϴ/ϴ scands 
from 2º to 60º 2ϴ with a step size of 0.026º 2ϴ. The measuring time was 200 seconds per 
step. 
To obtain FTIR spectra of PGZ, PLGA-PEG, and NSs a Thermo Scientific Nicolet iZ10 
with an ATR diamond and DTGS detector were used. The scanning range was 525–4000 
cm−1. 
DSC analysis was performed using a DSC 823e System (Mettler-Toledo, Barcelona, 
Spain). A pan with indium (purity ≥ 99.95 %; Fluka, Switzerland) proved ideal to check 
the calibration of the calorimetric system. An empty pan served as a reference. The DSC 
measurements were carried out on the PGZ, PLGA-PEG and NSs. On heating the samples 
(2.32–2.95 mg) from 25 ºC to 235 ºC at 10 ºC/min in a nitrogen atmosphere it was possible 
to evaluate the data from the peak areas using the Mettler STARe V 9.01 DB software 
(Mettler-Toledo). 
 
Release Profile of PGZ-NSs 
 
The Franz diffusion cell technique enabled PGZ release studies from NSs to be carried 
out giving models that explained the release of the drug from the polymer matrix. Behind 
this there is the direct dispersion of the NSs in the dialysis medium complying with sink 
conditions (20). For 24 hours a dialysis membrane was hydrated and then placed in the 
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Franz diffusion cell. The temperature of the medium and speed of the paddle were set at 
32.0 ± 0.5 °C and 100 rpm, respectively. The comparisons of the PGZ-NSs formulations 
were made with free drug (1 mg/ml) dissolved in DMSO and a phosphate buffer solution 
(PBS) (60:40), receptor solution (RS) at pH 7.4 for 15 hours to allow an estimated 
modeling. A volume of 0.3 ml of formulations was put in the donor compartment and the 
same medium was introduced for the solubilization of free drug in the receptor 
compartment. A volume of 0.3 ml was withdrawn from the receptor compartment at 
marked times and its place taken by an equivalent volume of RS at the same temperature. 
HPLC provided the released PGZ concentration. Values are reported as the average ± SD 
using six replicates. At each point of time, the released PGZ content was evaluated and 
the data were adjusted to the most common kinetic models (21). In each case Akaike’s 
information criterion (AIC) was determined: it was to be an indicator of the model’s 
suitability for a given set of data (22). 
 
Corneal and Scleral Permeation Studies 
 
Ex vivo corneal and scleral permeation experiments were carried out with pigs (male, 
weight 30-40 kg and group n=6). These were supervised by veterinary officials and were 
in accordance with the ethics committee of animal experimentation at the University of 
Barcelona. The pigs were anesthetized with intramuscular administration of ketamine 
HCl (3 mg/kg), xylazine (2.5 mg/kg) and midazolam (0.17 mg/kg). Once sedated, the 
Propofol (3 mg/kg) was administered by auricular vein and immediately afterwards they 
were intubated and maintained under anesthesia inhaled with isoflurane.  In order to 
induce pig euthanize, 250 mg/Kg of sodium pentobarbital were administered through the 
auricular ear vein under deep anesthesia. The cornea and sclera of the animals were cut 
away and placed in an artificial tear solution. The assay was carried out using Franz 
diffusion cells and the tissue was fixed between the donor and receptor compartment. The 
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area in which the permeation could work was 0.64 cm2. The receptor compartment was 
filled with a freshly prepared transcutol/water solution (60/40 v/v) and kept at 32.0 ± 0.5 
ºC and stirred continuously for 6 hours. Volumes of 0.2 ml from a solution containing 1 
mg/ml of PGZ-NSs and free drug solution (solubilized at the same receptor medium) 
were added to the donor compartment (covered with parafilm so that there should be no 
evaporation). A volume of 0.2 ml was taken from the receptor compartment at pre-
determined times and in its place an equivalent volume of transcutol/water solution was 
introduced at the same temperature. The cumulative PGZ amount permeated per unit area 
(μg/cm2) was worked out at each time in point from the PGZ concentration in the 
receiving medium and a graph drawn up as a function of time (h). All experiments were 
carried out under sink conditions. Samples were analyzed by HPLC. 
 
PGZ Amount Retained in the Cornea  
 
PGZ quantification in the ocular tissues was realized after 6 hours of the experiment. The 
cornea and sclera were cleaned using a 0.05 % solution of sodium lauryl sulfate and 
thoroughly rinsed with distilled water. They were weighed and during 30 minutes PGZ 
was extracted with methanol under sonication using an ultrasound bath. PGZ levels were 
expressed as μg/(g·cm2) of the cornea or sclera permeated and retained through the 
tissues. HPLC determined the PGZ. Results are reported as the average ± SD for the PGZ 
amount permeated and retained on each tissue, respectively. 
 
Ocular permeation parameters 
 
At every marked time the cumulative drug amounts (Qt) permeated through the cornea 
and sclera per unit area were noted. The retained amount (Qret) was calculated working 
from the amount extracted and the recovery percentage - information already available. 
The amount extracted (Qext) was calculated at the end of the experiment from the contact 
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area vs tissue weight, after sonication. PGZ flux (Jss) through the cornea and sclera from 
each formulation was calculated setting out on a graph the cumulative drug amount 
permeating the cornea and sclera over time. The slope of the linear portion of the curve 
was found by linear regression analysis and dividing it by the diffusion area. The 
permeability coefficient of the drug at the steady state (Kpss) from formulations was 
worked out using (Eq. 4):  
                                                           
            𝐾𝑝𝑠𝑠 =
𝐽𝑠𝑠
𝑐𝑜
                                        (4) 
 
being Jss the flux and co the initial drug concentration in the donor phase. 
 
Ocular Hydration Levels  
 
At the end of the corneal permeation assays, the level of ocular hydration (HL (%)) of 
cornea assessed was determined. Then, each cornea was gently released from the sclera 
ring, washed, weighed and desiccated at a constant weight and dried at 80 ºC and then 
reweighed. HL (%) was arrived at in line with a previous study (9) using (Eq. 5): 
  
                                   𝐻𝐿 (%) = [1 − (𝑤𝑑/𝑤𝑤)] ∙ 100                          (5) 
 
where 𝑤𝑑  is weight of the cornea after being dried and 𝑤𝑤 is the weight before being 
dried. Results are reported as the average ± SD of six replicates.  
 




When it came to evaluating the ocular tolerability of the developed formulation, the 
modified hen’s egg chorioallantoic membrane (HET-CAM) test was carried out. The 
potential irritancy of compounds may be detected by observing adverse changes that 
occur in the CAM of the egg after exposure to test chemicals (23). Briefly, fertilized hens’ 
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eggs were maintained at a temperature of 12 ± 1 oC not less than 24 hours before placing 
them in the incubator at a controlled temperature (37.8 ºC) and humidity (50-60 %), to 
stay there over the days of incubation.  
The shell was cut a little above the marked line of the chorioallantoic membrane (first this 
section of shell was removed). The inner membrane directly in contact with the CAM 
was dampened with 1 ml of 0.9 % saline solution, added with a pipette. The inner 
membrane was then removed with great care. It was important that no harm was done to 
the blood vessels, then it was possible to see the chorioallantoic membrane below. A 
volume of 0.3 ml of the studied formulation was then added directly by pipette onto the 
CAM. Analysis, hemorrhaging and/or coagulation at different times over a 5 minute 
period after the application of the test solution were written down, and any effect that 
stood out was compared with the controls: saline (negative) and sodium hydroxide 
(positive) solutions. Each test was performed 6 times. Data were analyzed as the average 
± SD of the time at which the injury had happened (n=6/group). The scores were recorded 




Tests on pigs (male, weight 30-40 kg) revealed the extent of the irritancy of the PGZ-NSs 
formulations. This assay was the primary eye irritation test following the methods set 
down by Draize (1944) and Kay et al., (1962), (n=6/group) (24,25). A volume of 0.05 ml 
of the sample from a concentration of 1 mg/ml, was administered in the conjunctival sac 
of the right eye: the untreated contra-lateral eye was a control. The level of irritation was 
assessed 1 hour after application of the formulation. An analysis  was carried out of ocular 
lesions in the cornea (opacity), iris (swelling, hemorrhage) and conjunctiva 
(inflammation, congestion, chemosis and discharge) guided by the ocular irritation index 
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(OII) by visual assessment looking for any changes in the cornea, conjunctiva and iris. 
(Table S2: b. Supplementary data). 
 
In vivo Bioavailability Study 
 
In order to investigate ocular bioavailability and disposition of PGZ, 6 hours after topical 
administration of 0.05 ml of PGZ-NSs from a concentration of 1 mg/ml, the pigs were 
euthanized and the ocular tissues, including the retina, cornea, lens, sclera, choroid, iris, 
aqueous humor and vitreous humor were isolated from the eyes and kept at – 80 ºC until 
liquid chromatography quantification of the PGZ amount - mass spectrometry (LC-MS) 
as the average ± SD (n=6/group). 
 
Cell Culture Cell Line (Y-79) 
The cytotoxicity of PGZ-NSs in comparison to the free PGZ was carried out in the Y-79 
cell line, exposed to different concentrations which went from 2 to 100 μg/ml, using the 
Alamar blue (AB) assay. AB (resazurin) is a sensitive oxidation-reduction metabolic 
indicator. Once it has entered the cells and in the presence of metabolic reducing 
equivalent molecules (originating from cell metabolism), it changes its coloration from 
blue to rose (and thus the absorbance spectra shifts). The Y-79 cells were kept in RPMI-
1640, supplemented with 10% (v/v) fetal bovine serum (FBS), 2 mM L-glutamine, and 
antibiotics (100 U/ml penicillin and 100 μg/ml of streptomycin) in an atmosphere of 5% 
CO2 in air at 37 ºC. The cells were centrifuged, re-suspended in culture media, the number 
recorded and seeded, once the appropriate dilution had been made, at 1·105 cells/ml in 
poly-L-lysine pre-coated 96-well plates (100 μg/well) for adherence, which was achieved 
in about 24 hours. After adherence, the culture medium was taken away and test solutions 
added in. PGZ-NSs and free PGZ were diluted with FBS-free culture medium to achieve 
the desired final concentrations (test solutions), and then introduced to the cells (0.1 
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ml/well). Microplates were placed in the incubator, and the cells were in contact with the 
test solutions for 24 or 48 hours. Once the exposure time was over, the media containing 
the NSs and the control were taken away and replaced by FBS-free medium supplemented 
with 10 % (v/v) of AB. The absorbance readings took place about 4-5 hours after AB 
addition, at 570 nm (reduced form) and 620 nm (oxidized form). A Multiskan EX 
microplate reader was employed (MTX Labsystems, USA). The cell viability was worked 
out by the percentage of AB reduction, using equations as recommended by AB 
manufacturers as described previously (26). 
In vivo Anti-inflammatory Assay  
To assess inflammation prevention, PGZ-NSs were tested in pigs (n=6/group). Firstly, 
there was just one instillation of a single dose administered at 0.05 ml of PGZ-NSs 
(concentration of 1 mg/ml) or 0.9 % (w/v) isotonic saline solution (control) in the 
conjunctival sac of the right eye. The contralateral eye acted as the untreated control. 
After 30 minutes, ocular inflammation was induced administering 0.05 ml of SA 0.5 % 
(w/v) dissolved in a phosphate buffer solution (pH 7.4) instilled in the right eye. From the 
first reading after 30 minutes, thereafter every 30 minutes a new reading was made of the 
inflammation to measured it up to three hours (180 minutes) after the instillation of SA. 
The level of inflammation was quantified through ocular changes, in line with a modified 
Draize scoring system (27), which are shown as the sum of the inflammation scores 
expressed as the average ± SD of six replicates. 
Statistical Analysis 
 
The GraphPad Prism 6.0 software package was used to analyze the data. The student's t-
test was used for two-group comparisons and Statgraphics Plus 5.1 software. To analyze 
the factorial design, statistical evaluation of data was carried out using a one-way analysis 
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of variance (ANOVA) test. Differences were taken as statistically significant when the p-
value fell below 0.05. All of the data are presented as the average ± SD.  
 
RESULTS AND DISCUSSION  
 
Factorial Design and Characterization of PGZ-NSs 
 
The experiments design was used to optimize the parameters, in order to obtain particles 
suitable for ocular administration. The results of factorial design ranged from Zav 148.9 
to 165.4 nm with monomodal distribution, PI values between 0.08 and 0.17 (Table I). 
There were no statistically significant effects noticeable when morphometric properties 
were indicated as responses. ZP values ranged from -10.1 to -15.6 mV, and were greatly 
influenced by PGZ concentration (Fig. 1A), with a coefficient of determination of 0.93. 
A low PGZ concentration allows the obtaining of high negative ZP values which can 
increase the stability of these systems. In the Pareto diagram (Fig. S1: B. Supplementary 
data) the influence of PGZ concentration on the ZP was observed. The EE values ranged 
from 81.19% to 94.47 %, and showed a significant decrease at high PGZ concentrations 
(Fig. 1B). This could be put down to the fact that the PGZ concentration indirectly 
influences encapsulation (r2=0.94). For these reasons, in order to obtain an equilibrium 
between stability and high EE, the replicate formulation (F15 and F16) was selected (1 
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The optimized PGZ loaded PLGA-PEG NSs, made by solvent displacement technique, 
showed a Zav around 160.0 ± 1.3 nm, with PI values in the range of monodisperse systems 
(PI < 0.1) and high association efficiency (92 %), which is suitable for ophthalmic 
application. The ZP that could be considered as a parameter of stability and 
mucoadhesion of these systems was -13.9 mV, indicating an adequate short-time stability. 
To determine the size and surface morphology of the optimized PGZ-NSs TEM was the 
method chosen (Fig. 2), evidencing that PGZ-NSs are spherical in morphology.  
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Fig. 2.:  
 
Interactions Studies  
 
The in vivo and in vitro release of drugs from delivery systems could be influenced by the 
physical state of drugs in the colloidal systems. Therefore, different combinations of 
drug/polymer could coexist in the bulk, and these would be: (i) amorphous drug in either 
an amorphous or a semi-crystalline polymer or (ii) crystalline drug in either an amorphous 
or a semi-crystalline polymer. This leads on to it being possible that the drug may be 
present as either a solid solution or as a solid dispersion in an amorphous or semi-
crystalline polymer (19). Herein lies why it is necessary to be aware of the interactions 
between the polymer and the drug. 
Fig. 3A sets out the X-ray diagrams of PGZ, PLGA-PEG and NSs. The X-ray spectrum 
of PGZ powder showed sharp crystalline peaks, whereas PLGA-PEG and NSs, according 
to their profiles, were amorphous. These results suggested that when the drug was loaded 
under the form of NSs, showed a similar polymer profile. This fact can be clearly seen in 
the detail of Fig. 3A.  
FTIR analysis suggests that there is no evidence of new covalent bonds, between the drug 
and the polymer (Fig. S2. Supplementary data). These results are what can be expected 
in line with those set forth by other authors (21). 
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The DSC profiles of PGZ showed an endothermic event between 153.63 ºC to 209.15 ºC, 
which corresponded to solid-liquid transition (Tmax of 196.54 ºC and H of138.00J/g), 
followed by another thermic event that corresponded to drug decomposition. The polymer 
showed an endothermic event attributed to glass transition (Tg) (midpoint ISO of 43.81 
ºC and onset of 43.03 ºC). PGZ-NSs showed a thermic event that corresponds to glass 
transition (Tg) of the polymer in the form of NSs (midpoint ISO of 40.98 ºC and onset of 
38.82 ºC). The Tg parameters decrease in the NSs is probably due to a plastic effect 
exerted by the drug on the polymer. As there is no endotherm corresponding to the drug 
fusion this indicates that the PGZ is in the form of either a molecular dispersion or a solid 
solution (Fig. 3B). These results are similar to those obtained by lipophilic drugs in the 











Fig. 3.:  
 
In vitro Release Profile 
 
The release profiles of PGZ-NSs and free PGZ (Fig. 4A), performed at 32 ºC, were the 
same model for both formulations. However, free drug was released faster than PGZ-NSs. 
In the first hour, both formulations showed fast release profiles, with 87.35 µg to free 
solution and 57.80 µg to PGZ-NSs, there being enough quantity to permeate the ocular 
tissues. This result contrasts with the results of permeations. Since the NSs adhere to the 
cornea and sclera, and due to the fact that this also happens on the surface of tissues, there 
is more contact and penetration of the drug (10, 28). 
The maximum amounts released (Ymax) from the drug free solution and PGZ-NSs were 
221.70 and 229.60 µg respectively, being significantly different among the formulations 
(p value = 0.0487). This assay showed a profile Fick’s passive diffusion with a constant 
of dissolution (K) of 0.44 h-1 and 0.28 h-1 for free drug and NSs, respectively. The free 
solution has a release rate 1.6 times faster than NSs, this being significantly slower (p = 
0.0001), although at 30 minutes the PGZ released was 38.83 versus 55.23 μg from free 
solution. This leads to the conclusion that PGZ release from NSs follows the same course 
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as a concentration gradient pattern, based on the Fick’s first law. These results are in line 
with other studies (8). 
In general, the release of the drug from PLGA-PEG particles can occur through diffusion, 
erosion of the polymer or a combination thereof. If the diffusion of the drug progresses at 
a higher speed than the degradation of the matrix, the mechanism of drug release makes 
itself felt mainly by diffusion (29). 
After 11 hours, a gradual release behavior was shown, where the entrapped PGZ very 
gradually diffused out of the polymeric matrix into the release medium. According to the 
AIC and coefficient of determination (r2) values obtained, the best fitting for all 




Table II. Parameters of release profile 
 
      Kinetics Models                    Free PGZ                 PGZ-NSs  
AIC                      r2  AIC                       r2       
One exponential association  
𝑄𝑡 = 𝑄∞ ∙ (1 − 𝑒
−𝐾∙𝑡)                           62.3                   0.974                 111.3                   0.977 
                                                                                                            
Hyperbola                                
𝑄𝑡 = 𝑄∞ ∙ 𝑡/(𝐾 + 𝑡)                             63.0                   0.971                  113.2                  0.974 
                                                                                                                           
Zero order                                
𝑄𝑡 = 𝐾0  ∙ 𝑡 + 𝑄∞                                  79.0                   0.713                  138.5                  0.814 
                                                                
Korsmeyer Peppas                   
𝑄𝑡 = 𝐾 ∙ 𝑡
𝑛                                            69.0                   0.931                  123.0                  0.944 
                                                                                                         
𝑄𝑡 = cumulative amount of drug release at time t; 𝑄∞= maximum amount of drug released; 𝐾0, K = release rate constants; t = time  






Ex vivo Permeation Studies  
 
The transcorneal and transcleral permeation studies (Fig. 4B and C, respectively), carried 
out for 6 hours, showed different profiles for each one. In the statistical analysis of Jss and 
Qret, cornea and scleral expressed significant differences (p < 0.0001) when one compares 
the PGZ-NSs versus free PGZ (Table III). The value of Jss of the PGZ in cornea and sclera 
were similar for free drug. The PGZ from NSs permeates less through the cornea than 
sclera, showing that the cornea has a barrier effect three times higher than the sclera (30).  
This is a consequence of the cornea having a regular cellular order, while the cells of the 
sclera have a more irregular cellular arrangement (31). Another factor is the 
physicochemical properties of the molecule, which better interacts with scleral tissue, as 
well as other molecule properties favoring good scleral permeability, such as 
Triamcinolone (32). The permeability from NSs is important because these systems 
facilitate the permeation of faintly water-soluble drugs, in this case the PGZ.  
The Kpss is proportional to the Jss, therefore this parameter is smaller in the corneal than 
than in scleral tissue. To quantify both tissues, Qret of PGZ from NSs was higher than free 
drug. In both the Qret of PGZ were similar in the corneal tissue.  
The Qret in the sclera showed significant differences from PGZ-NSs to free drug 87.9 and 
72.47 µg/(g⋅cm2), respectively. The high permeability and accumulation of PGZ from 
NSs in the scleral tissue could be attribute to a better activity of these systems for posterior 
ocular diseases, as well as uveitis, probably due to high sclera permeability (33). These 
findings are in line with those obtained previously, which revealed that the PGZ could be 
effective for the treatment to endogenous uveitis (3). In another study, it was shown that 
PPARα agonist medical care significantly lessens inflammatory cell infiltration, total 
protein concentration, vessel density, and the development of inflammatory cytokine 
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(34). After 1 hour, the permeated quantify of PGZ from NSs in sclera was 5.6 µg in 
comparison with 1 µg in the cornea, it being sufficient to cross both tissues.   
 
(A) 





















                      
 




Table III. Parameters of ocular permeation.  
 
                  Corneal permeation                 Scleral permeation   
    Free PGZ              PGZ-NSs                    Free PGZ            PGZ-NSs                    
Jss (µg/(cm
2·h))                      2.33 ± 0.04 a            0.55 ± 0.01                2.59 ± 0.05 b         1.75 ± 0.01 
                                                                                                          
Kp (cm/h)                                2.33 ± 0.02             0.56 ± 0.03                2.59 ± 0.03           1.75 ± 0.01                                                                                                           
 
Qext (µg/(g·cm
2))                     22.63 ± 1.34           23.08 ± 2.14              16.68 ± 2.43         20.23 ± 3.05                         
 
Qret (µg/(g·cm
2))                     26.64 ± 0.07 a          27.17 ± 0.05              72.47 ± 0.12 b       87.90 ± 0.25 
                                                                                                         
𝐽𝑠𝑠 = Flux; 𝐾𝑝= permeability coefficient of the drug at the steady state; 𝑄𝑒𝑥𝑡  = extracted amount; 𝑄𝑟𝑒𝑡  = retained amount. 
Parameters values are expressed as average ± SD; a,b p < 0.0001. a = Comparison between Free PGZ vs PGZ NSs with cornea  
tissue. b = Comparison between Free PGZ vs PGZ NSs with sclera tissue. 
28 
 
Ocular Hydration Levels 
 
The HL (%) is frequently taken as a parameter to measure the harm done to the cornea 
tissue. The normal cornea has a hydration level of 76–80 % (35). A HL level of 3–7 % 
greater than the normal value indicates damage to the epithelium or endothelium. The HL 
percentage obtained for PGZ-NSs (79.82 %) has shown that it can be accepted as being 
within an adequate range, and does not cause any harm to the corneal tissue (Table S1: 
Supplementary data). This result is in accordance with that obtained for controlled release 
systems and transcutol® P (7).  
 
Tolerance Ocular Assays (HET CAM® and Draize Test) 
The in vitro potential irritation was detected by the HET CAM test. The CAM is a 
membrane with such vascularity that it has structure similar to other highly vascularized 
tissues. Moreover, the conjunctiva is an ideal model for ocular irritation studies. A volume 
of 0.3 ml of PGZ-NSs was administered to the CAM for 5 minutes and there was no 
irritation. Hemorrhage, vascular lysis or coagulation were not seen in any way. An OII of 
0.4 was the score, indicating that these systems are safe for application to the eye.  
In the in vivo studies pigs were used in order to analyze the ocular tolerance level (Draize 
test) of the PGZ-NSs. No irritations or damaging effects were detected after the PGZ-NSs 
had been instilled, being the OII = 0 at all the points. This assay indicated an optima 
ocular tolerance and was reinforced by the results obtained from the Hen’s Egg test (HET-
CAM). In accordance with other authors, polymeric NSs are safe for ocular 






In vivo Bioavailability Study 
In order to determine the in vivo bioavailability studies, the PGZ-NSs were administered 
post topically for 6 hours, quantified in different eye tissues. Different levels of PGZ were 
obtained from the PGZ-NSs in the ocular tissues as well as in the retina (30.78 µg/g), 
cornea (20.52 µg/g), lens (13.45 µg/g), sclera (64.45 µg/g), choroid (159.67 µg/g), iris 
(117.25 µg/g), aqueous humor (9.60 µg/ml) and vitreous humor (9.20 µg/ml). The values 
are expressed by mean ± SD (n=6) (Fig. S4. Supplementary data). 
These results are in accordance with those obtained in ex vivo corneal and scleral 
permeation studies. The PGZ exhibited higher levels in the scleral tissue, demonstrating 
that this drug could be useful to treat diseases affecting the posterior segment of the eye. 
However, through tests with small amounts of the drug it has been revealed that PGZ 
encapsulated in NSs achieves a release reaching many parts of the eye, including the 
retina. Further studies could be carried out to show new routes for the effectiveness of the 
agonist of PPARγ against ocular inflammatory diseases. The NSs could be a new strategy 
for the delivery of PGZ into the eye, also leading to a reduction in the adverse effects. 
 
Toxicity Assay 
The cell viability (expressed as % of control) was carried out in human retinoblastoma 
cell line, Y-79, which were exposed to test the solution of PGZ-NSs, free PGZ and Tw80 
2%, diluted in FBS-free culture media to the final concentrations of 2, 10, 20, 50 and 100 
µg/ml. The AB indicator was used to measure quantitatively the viability and propagation 
of the cells, rendering measurable the toxicity of tested agents/drugs in relation to non-
exposed cells (control). It is possible to observe that the free drug did not produce any 
toxicity in the concentrations and exposure times analyzed, as the viability is always 
greater than 80% of control (Fig. 5). The PGZ-NSs, up to 10 µg/ml, shows no toxicity, as 
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cell viability is above 80%, but doubling the concentration to 20 µg/ml shows a drastic 
reduction in cell viability with the percentage values being close to zero. Meanwhile, 
when the effect of Tw 80 (at 2 % in the particles) was analyzed, it showed a similar profile 
of toxicity as that seen in PGZ-NSs up to 10 µg/ml, with 80 % of viability. The decrease 
of the level of cell viability (%) induced by PGZ-NSs leads one to believe in an interaction 
of Tw 80 (not fully incorporated into the NSs or that leaked from the NSs) with the cell 
membranes, leading to their lysis. It is worth mentioning that this is an in vitro assay in 
which the living cells are directly exposed to the NSs and their components. The 
administering of these solutions directly to cells, and the systems used, exposing the cells’ 
membranes to their components, is quite different from the administering of these 
solutions, with these systems, to the ocular organ. The application of these systems by the 
ocular route is non-toxic since the NSs are placed on the cornea and not directly on the 
cells (with the exposed cell membranes). According to previous reports, Tw 80, in 
comparison with other surfactants, showed the lowest cytotoxicity when tested in normal 
human fibroblast cultures (37). 
These in vitro results contrast with the in vivo assays of ocular tolerance that show that 
NSs is non-irritant. This comparison corroborates the fact that the cornea works as a 
barrier, protecting the cells from NSs aggressive components while permitting the 




                                                                                
Fig. 5.:  
 
In vivo Anti-inflammatory Efficacy 
 
With the aim of evaluating the anti-inflammatory efficacy of PGZ-NSs in the prevention 
of ocular inflammation processes, PGZ-NSs were administered to the pigs 30 minutes 
before inducing inflammation with SA. PGZ-NSs showed significant differences 
regarding the positive control for the first 30 minutes after SA administration (p = 
0.0008), reducing the degree of conjunctival inflammation and iris hyperemia 
significantly, as shown in (Fig. 6). It may be due mainly to the quantity of PGZ provided 
by NSs in different tissues, resulting in a reservoir effect of the drug and promoting the 
continuity of the pharmacological action. These results demonstrate that PGZ in reduced 
doses is an effective therapeutic agent for ocular inflammation, possibly increasing drug 
effect by encapsulation in polymeric NSs. 
It was showed by ocular permeation that free PGZ is distributed and retained in cornea 
and sclera in smaller proportions whereas PGZ-NSs provide higher drug levels in the 
sclera and cornea, as well as higher drug penetration in different tissues of the eye. A 
study showed that PGZ might improve impaired insulin signaling in the diabetic rat retina 
(38). Another study provide evidence that TZDs may have the potential to inhibit the 
progression of diabetic retinopathy (39). However, it has been described that an 
ophthalmic solution containing 0.1% PGZ inhibited inflammation, decreased the fibrotic 
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reaction, and prevented corneal neovascularization in the cornea from the early phase 
after alkali burn injury in rats (4). However, in another study, it was shown that the PGZ 
inhibited intraocular concentrations of TNF-α and IL-6 in the endogenous uveitis model 
(2). These results demonstrated that PPARγ agonists may represent a way of moving 
forward with a treatment strategy focused on clinical applications in inflammatory 
processes and better wound healing. This data obtained could also suggest that the 
dispersion of the drug within the polymer in the form of NSs favors and thus adds to its 
ocular bioavailability. 
 
                       




In summary, our study demonstrated that PGZ-NSs developed by the displacement 
technique were characterized with an Zav appropriate for ocular administration (around 
160 nm), suitable ZP, high EE (92 %) and a good homogenization characteristic of 
monodisperse systems. The interaction studies showed that the potential of PGZ-NSs as 
a drug carrier system in which drug dispersion in the polymer increases the PGZ 
solubility. This is because the drug has a plastic effect on the polymer. 
The release profile corresponds to Fick’s passive diffusion, followed by a slower and 
continuous release. The permeation studies of NSs through the cornea and sclera 
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demonstrated higher Qret of PGZ in the sclera 87.9 µg/(g⋅cm2), which was corroborated 
in the bioavailability studies. The percentage of HL for the PGZ-NSs was within the 
normality parameters (79.82 %). No irritation or damaging effects were detected in the 
HET CAM and Draize Test. Cytotoxicity studies of the colloidal systems showed no 
toxicity up to 10 µg/ml. The in vivo assay showed promising effects of the PGZ-NSs with 
respect to preventing inflammation. Taken together, the results of this study suggest that 
the PGZ-NSs show anti-inflammatory activity, which could be useful for the prevention 
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Legend to Figures 
 
Fig.1: Surface response of PGZ-NSs at 9.5 mg/ml PLGA-PEG concentration. (A) PGZ 
and Tw 80 concentrations influence on the NSs ZP. (B) PGZ and Tw 80 concentrations 
influence on the NSs EE. 
 
Fig. 2: Transmission electron microphotograph of the PGZ-NSs. 
 
Fig. 3. Interactions studies. (A) X-ray diffraction patterns. (B) Differential scanning 
calorimetry. 
 
Fig. 4: Biopharmaceutical behavior. (A) In vitro release profile of PGZ-NSs and Free 
PGZ. (B) Transcorneal permeation. (C) Transcleral permeation. 
Parameters values are expressed as average ± SD; ****p < 0.0001. 
 
Fig. 5.: Cell viability of Y 79 cells exposed to PGZ-NSs, Free PGZ and Tw 80 2% at 
different concentrations. 
 
Fig. 6.: Comparison of anti-inflammatory efficacy after SA-induced inflammation in the 
pig’s eye. 
Values are expressed as average ± SD; ***p = 0.0008 ****p < 0.0001 significantly 









   
